RAIDD/CRADD Antibody Blocking Peptide

• Reactivity: Hu
• Applications: AC
• Concentration: 0.2 mg/ml

RAIDD/CRADD Antibody Blocking Peptide Summary

• Description: A blocking peptide containing 19 amino acids near the center of human RAIDD.

  Source: Synthetic

  (Accession #: AAB42217)

• Source: Synthetic
• Protein/Peptide Type: Antibody Blocking Peptide
• Gene: CRADD
• Purity: N/A

Applications/Dilutions

• Dilutions:
  • Antibody Competition
• Application Notes: This peptide is useful as a blocking peptide for NBP1-77061.
  
  For further blocking peptide related protocol, click here.

Packaging, Storage & Formulations

• Storage: Store at -20C. Avoid freeze-thaw cycles.
• Buffer: PBS pH 7.2 (10 mM NaH2PO4, 10 mM Na2HPO4, 130 mM NaCl) containing 0.1% bovine serum albumin.
• Preservative: 0.02% Sodium Azide
• Concentration: 0.2 mg/ml
• Purity: N/A

Alternate Names for RAIDD/CRADD Antibody Blocking Peptide

• CASP2 and RIPK1 domain containing adaptor with death domain
• Caspase and RIP adapter with death domain
• caspase and RIP adaptor with death domain
• CRADD
• death domain containing protein CRADD
• death domain-containing protein CRADD
• MGC9163
• RAIDD
• RAIDDdeath adaptor molecule RAIDD
• RIP-associated ICH1/CED3-homologous protein with death domain
• RIP-associated protein with a death domain

Background

Apoptosis is triggered by activation of initiator caspases upon complex-mediated clustering of the inactive zymogen, as occurs in the caspase-9-activating apoptosome complex. Activation of caspase-2 occurs in a complex that contains the death domain-containing protein PIDD, whose expression is induced by p53, and the adaptor protein RAIDD (1). RAIDD has a dual-domain structure similar to that of FADD. It has an NH2-terminal caspase homology domain that interacts with caspase-2 and a COOH-terminal DD that interacts with RIP. RAIDD is constitutively expressed in many tissues and thus could play a role in regulating apoptosis in mammalian cells (2). In metazoan cells there exists inactive polypeptide precursors (zymogens), each composed of a prodomain, which is cleaved to activate the protease, and a large and small catalytic subunit. The coupling of these proteases to signaling pathways is probably mediated by adaptor molecules that contain protein-protein interaction motifs such as the death domain (3).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

Bioinformatics

• Gene Symbol: CRADD